The director of the (National Health Surveillance Agency) Thiago Campos stated that the limit of 0.3% THC (tetrahydrocannabinol) defined for the cultivation of cannabis in Brazil does not prevent the production of medicines with higher concentrations of the substance. The speech was made in an interview with the podcast that aired this Tuesday (10.Feb.2026).
According to Campos, the established percentage only applies to cultivation authorized by small associations and communities and does not limit the THC content of the final products. “0.3% is not a limit for the THC content of cannabis products and medicines that may be registered”, he stated.
On February 3, 2026, Anvisa published rules that allow the cultivation of cannabis with a THC content equal to or less than 0.3%. Before that, planting was prohibited in the country, except for authorizations granted by the Court. Campos reported the process at the agency and said that the percentage represented the possible consensus among the directors.
“That’s what we could agree on. It’s better to take a safe step and move forward in the future”he stated. He stated that he defended a higher limit, but agreed with the approved proposal.
The director also stated that there is no intention to restrict the import of cannabis-based medicines. According to him, Anvisa should not adopt measures that limit patients’ access to necessary treatments. RDC 660, which authorizes imports, serves around half of the patients who use medicinal cannabis in the country. Here is it (PDF – 54 KB).
Campos also said that there are no studies that justify the creation of a specific agency to regulate cannabis. According to him, Anvisa has the competence to deal with the issue and conduct regulation.
